OR WAIT null SECS
Cytovance Biologics completes GMP manufacture of ARMO BioSciences& lead product.
Cytovance Biologics, a contract manufacturer of mammalian and microbial biologics, has announced the successful completion of GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10).
ARMO BioSciences, a clinical stage biotechnology company based in Redwood City, CA, is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases.
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. The company also offers process development, cGMP cell banking, and support services from its Oklahoma City facilities.
Source: Cytovance Biologics